Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis

Journal of the American Academy of Dermatology

Volumn 68, Issue 1, 2013, Pages 64-72

  Yeung, Howa ^a   Wan, Joy ^a   Van Voorhees, Abby S ^a   Callis Duffin, Kristina ^c   Krueger, Gerald G ^c   Kalb, Robert E ^d   Weisman, Jamie D ^e   Sperber, Brian R ^f   Brod, Bruce A ^a   Schleicher, Stephen M ^g   Bebo Jr , Bruce F ^h   Shin, Daniel B ^a,b   Troxel, Andrea B ^b   Gelfand, Joel M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e Peachtree Dermatology Associates   (United States)

^f Dermatologic Surgery Unit   (United States)

^g DermDox Centers for Dermatology   (United States)

^h National Psoriasis Foundation   (United States)

Author keywords

biologics; cost; effectiveness; inconvenience; phototherapy; psoriasis; safety; systemic treatments; treatment discontinuation

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PATIENT SATISFACTION; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUVA; SELF REPORT; STRUCTURED INTERVIEW; TREATMENT DURATION; TREATMENT WITHDRAWAL; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT;

ACITRETIN; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KERATOLYTIC AGENTS; LOGISTIC MODELS; MALE; METHOTREXATE; MIDDLE AGED; PATIENT SATISFACTION; PSORIASIS; PUVA THERAPY; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84870939300     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.06.035     Document Type: Article

References (40)

1. A.B. Kimball, D. Gladman, J.M. Gelfand, K. Gordon, E.J. Horn, and N.J. Korman National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening J Am Acad Dermatol 58 2008 1031 1042
2. J.M. Gelfand, A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, and A.B. Troxel Risk of myocardial infarction in patients with psoriasis JAMA 296 2006 1735 1741
3. K. Abuabara, R.S. Azfar, D.B. Shin, A.L. Neimann, A.B. Troxel, and J.M. Gelfand Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK Br J Dermatol 163 2010 586 592
4. Y.B. Brauchli, S.S. Jick, M. Miret, and C.R. Meier Psoriasis and risk of incident myocardial infarction, stroke or transient ischemic attack: an inception cohort study with a nested case-control analysis Br J Dermatol 160 2009 1048 1056
5. Y.J. Chen, Y.T. Chang, J.L. Shen, T.T. Chen, C.B. Wang, and C.M. Chen Association between systemic anti-psoriatic drugs and cardiovascular risk in patients with psoriasis and psoriatic arthritis: a nationwide cohort study Arthritis Rheum 64 2012 1879 1887
6. D.D. Gladman, M. Ang, L. Su, B.D. Tom, C.T. Schentag, and V.T. Farewell Cardiovascular morbidity in psoriatic arthritis Ann Rheum Dis 68 2009 1131 1135
7. S. Prodanovich, F. Ma, J.R. Taylor, C. Pezon, T. Fasihi, and R.S. Kirsner Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis J Am Acad Dermatol 52 2005 262 267
8. O. Ahlehoff, G.H. Gislason, M. Charlot, C.H. Jorgensen, J. Lindhardsen, and J.B. Olesen Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study J Intern Med 270 2011 147 157
9. O. Ahlehoff, G.H. Gislason, J. Lindhardsen, J.B. Olesen, M. Charlot, and L. Skov Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study J Intern Med 270 2011 237 244
10. W.Q. Li, J.L. Han, J.E. Manson, E.B. Rimm, K.M. Rexrode, and G.C. Curhan Psoriasis and risk of nonfatal cardiovascular disease in US women: a cohort study Br J Dermatol 166 2012 811 818
11. H. Maradit-Kremers, M. Icen, F.C. Ernste, R.A. Dierkhising, and M.T. McEvoy Disease severity and therapy as predictors of cardiovascular risk in psoriasis: a population-based cohort study J Eur Acad Dermatol Venereol 26 2012 336 343
12. T. Nijsten, D.J. Margolis, S.R. Feldman, T. Rolstad, and R.S. Stern Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey J Am Acad Dermatol 52 2005 434 444
13. R.S. Stern, T. Nijsten, S.R. Feldman, D.J. Margolis, and T. Rolstad Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction J Investig Dermatol Symp Proc 9 2004 136 139
14. G. Krueger, J. Koo, M. Lebwohl, A. Menter, R.S. Stern, and T. Rolstad The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey Arch Dermatol 137 2001 280 284
15. H.L. Richards, D.G. Fortune, T.M. O'Sullivan, C.J. Main, and C.E. Griffiths Patients with psoriasis and their compliance with medication J Am Acad Dermatol 41 1999 581 583
16. E.J. Horn, K.M. Fox, V. Patel, C.F. Chiou, F. Dann, and M. Lebwohl Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey J Am Acad Dermatol 57 2007 957 962
17. M. Augustin, B. Holland, D. Dartsch, A. Langenbruch, and M.A. Radtke Adherence in the treatment of psoriasis: a systematic review Dermatology 222 2011 363 374
18. S.R. Feldman, C. Evans, and M.W. Russell Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan J Dermatolog Treat 16 2005 37 42
19. A.M. Brunasso, M. Puntoni, C. Salvini, C. Delfino, P. Curcic, and A. Gulia Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients Acta Derm Venereol 91 2011 44 49
20. R. Gniadecki, K. Kragballe, T.N. Dam, and L. Skov Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris Br J Dermatol 164 2011 1091 1096
21. M. Lebwohl A Clinician's paradigm in the treatment of psoriasis J Am Acad Dermatol 53 Suppl 2005 S59 S69
22. K.K. Brown, W.E. Rehmus, and A.B. Kimball Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis J Am Acad Dermatol 55 2006 607 613
23. R.A. Elliott, N. Barber, and R. Horne Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence Ann Pharmacother 39 2005 508 515
24. S. Fouere, L. Adjadj, and H. Pawin How patients experience psoriasis: results from a European survey J Eur Acad Dermatol Venereol 19 Suppl 2005 2 6
25. M.L. Schaarschmidt, A. Schmieder, N. Umar, D. Terris, M. Goebeler, and S. Goerdt Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes Arch Dermatol 147 2011 1285 1294
26. J.M. Gelfand, J. Wan, K. Callis Duffin, G.G. Krueger, R.E. Kalb, and J.D. Weisman Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting Arch Dermatol 148 2012 487 494
27. D.M. Pariser, J. Bagel, J.M. Gelfand, N.J. Korman, C.T. Ritchlin, and B.E. Strober National Psoriasis Foundation clinical consensus on disease severity Arch Dermatol 143 2007 239 242
28. J.E. Mezzich, H.C. Kraemer, D.R. Worthington, and G.A. Coffman Assessment of agreement among several raters formulating multiple diagnoses J Psychiatr Res 16 1981 29 39
29. S. Rabe-Hesketh, A. Skrondal, and A. Pickles GLLAMM manual; working paper 160 2004 UC Berkeley Division of Biostatistics Working Paper Series Berkeley (CA)
30. S. Tyring, K.B. Gordon, Y. Poulin, R.G. Langley, A.B. Gottlieb, and M. Dunn Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis Arch Dermatol 143 2007 719 726
31. L.L. Lecluse, R.J. Driessen, P.I. Spuls, E.M. de Jong, S.O. Stapel, and M.B. van Doorn Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis Arch Dermatol 146 2010 127 132
32. A. Menter, S.R. Feldman, G.D. Weinstein, K. Papp, R. Evans, and C. Guzzo A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis J Am Acad Dermatol 56 2007 31.e1-15
33. J.H. Saurat, G. Stingl, L. Dubertret, K. Papp, R.G. Langley, and J.P. Ortonne Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 2008 558 566
34. I. Schafer, J. Hacker, S.J. Rustenbach, M. Radtke, N. Franzke, and M. Augustin Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment Eur J Dermatol 20 2010 62 67
35. J. Schmitt, Z. Zhang, G. Wozel, M. Meurer, and W. Kirch Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-Analysis of randomized controlled trials Br J Dermatol 159 2008 513 526
36. A.M. Brunasso, M. Puntoni, and C. Massone Drug survival rates of biologic treatments in patients with psoriasis vulgaris Br J Dermatol 166 2012 447 449
37. J. Wan, K. Abuabara, A.B. Troxel, D.B. Shin, A.S. Van Voorhees, and B.F. Bebo Jr. Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients J Am Acad Dermatol 66 2012 376 386
38. J.P. Staidle, T.S. Dabade, and S.R. Feldman A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency Expert Opin Pharmacother 12 2011 2041 2054
39. B.A. Yentzer, C.B. Yelverton, G.L. Simpson, J.F. Simpson, W. Hwang, and R. Balkrishnan Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis Dermatol Online J 15 2009 1
40. A.W. Evers, M.M. Kleinpenning, T. Smits, J. Boezeman, P.C. van de Kerkhof, and F.W. Kraaimaat Treatment nonadherence and long-term effects of narrowband UV-B therapy in patients with psoriasis Arch Dermatol 146 2010 198 199